Following on from information provided to NICE by the company in March 2022, the appraisal of Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3997 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 April 2023 | Discontinued. Following on from information provided to NICE by the company in March 2022, the appraisal of Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 April 2022 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Baricitinib for treating active autoantibody-positive systemic lupus erythematosus ID3997. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual